Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Mill

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Leukemia|March 3, 2021
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphomaWarren Fiskus, Christopher P Mill, Dimuthu Perera, et al.
Blood Cancer Journal|April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Blood Cancer Journal|January 17, 2019
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cellsWarren Fiskus, Tianyu Cai, Courtney D DiNardo, et al.
Blood|February 24, 2026
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitorWarren Fiskus, Christopher P Mill, Ghayas C Issa, et al.
Pharmacological Reviews|January 6, 2022
The Yin and Yang of ERBB4: Tumor Suppressor and OncoproteinLauren M Lucas, Vipasha Dwivedi, Jared I Senfeld, et al.
Blood Advances|August 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phaseWarren Fiskus, Lucia Masarova, Christopher P Mill, et al.
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Leukemia|March 3, 2021
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphomaWarren Fiskus, Christopher P Mill, Dimuthu Perera, et al.
Blood Cancer Journal|April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Blood Cancer Journal|January 17, 2019
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cellsWarren Fiskus, Tianyu Cai, Courtney D DiNardo, et al.
Blood|February 24, 2026
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitorWarren Fiskus, Christopher P Mill, Ghayas C Issa, et al.
Pharmacological Reviews|January 6, 2022
The Yin and Yang of ERBB4: Tumor Suppressor and OncoproteinLauren M Lucas, Vipasha Dwivedi, Jared I Senfeld, et al.
Blood Advances|August 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phaseWarren Fiskus, Lucia Masarova, Christopher P Mill, et al.
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Pageof 4